Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Novel anti-CD23 antibody granted Fast Track and Orphan Drug designations
Advertisement
Biogen Idec announced that it has initiated a randomized, controlled, registration trial of an investigational anti-CD23 monoclonal antibody, lumiliximab, for patients with chronic lymphocytic leukemia (CLL). The trial will compare treatment with lumiliximab in combination with fludaribine, cyclophosphamide and rituximab (FCR), an emerging standard of care, to FCR alone in patients with CLL that has relapsed or failed to respond to initial therapy.
Biogen Idec also announced that lumiliximab was granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) for the above indication. Biogen Idec owns the worldwide rights to lumiliximab.
The newly initiated lumiliximab registration trial enrolled the first randomized U.S. patient January 17, 2007. The patient was treated on January 22, 2007, by Kelly Pendergrass, M.D., at Kansas City Cancer Center in Kansas City, Mo. The first international patient was also treated on January 22, 2007, by Dr. Paul Cannell at Royal Perth Hospital in Perth, Australia. The study will ultimately enroll approximately 276 patients worldwide at more than 90 centers.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer - National Cancer Institute grants $1M to test 3 chemo drugs
Pioneering discovery of an odor-detecting receptor enhancer
Modified crops reveal hidden cost of resistance
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program - First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
UF study strengthens concerns about long-term use of certain painkillers
Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.
